Gennex Laboratories Ltd
BSE:531739
Gennex Laboratories Ltd
BSE:531739
Price:
11
INR
-2.14%
Market Closed
Market Cap:
₹2.7B
Balance Sheet
Balance Sheet Decomposition
Gennex Laboratories Ltd
Gennex Laboratories Ltd
Balance Sheet Decomposition is not available for
Gennex Laboratories Ltd
Gennex Laboratories Ltd
Balance Sheet
Gennex Laboratories Ltd
Gennex Laboratories Ltd
Currency: INR
| Mar-2009 | Mar-2010 | Mar-2011 | Mar-2012 | Mar-2013 | Mar-2014 | Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||
| Cash & Cash Equivalents |
2
|
0
|
9
|
22
|
3
|
4
|
6
|
8
|
6
|
10
|
31
|
9
|
11
|
83
|
151
|
610
|
556
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
8
|
6
|
10
|
30
|
7
|
9
|
80
|
145
|
605
|
550
|
|
| Cash Equivalents |
2
|
0
|
9
|
22
|
3
|
4
|
6
|
0
|
0
|
1
|
2
|
2
|
2
|
3
|
6
|
5
|
6
|
|
| Short-Term Investments |
2
|
3
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
215
|
189
|
73
|
553
|
708
|
|
| Total Receivables |
185
|
49
|
34
|
54
|
100
|
141
|
155
|
151
|
227
|
243
|
181
|
246
|
89
|
113
|
94
|
178
|
142
|
|
| Accounts Receivables |
98
|
1
|
1
|
1
|
40
|
49
|
62
|
70
|
103
|
105
|
104
|
63
|
89
|
113
|
94
|
178
|
142
|
|
| Other Receivables |
87
|
48
|
33
|
53
|
60
|
92
|
93
|
82
|
124
|
138
|
77
|
183
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
8
|
16
|
19
|
22
|
19
|
19
|
13
|
29
|
29
|
23
|
53
|
74
|
50
|
77
|
157
|
252
|
359
|
|
| Other Current Assets |
1
|
2
|
2
|
4
|
1
|
0
|
0
|
0
|
0
|
0
|
25
|
21
|
12
|
9
|
12
|
26
|
47
|
|
| Total Current Assets |
198
|
69
|
66
|
104
|
124
|
163
|
173
|
190
|
262
|
277
|
290
|
350
|
377
|
472
|
487
|
1 618
|
1 811
|
|
| PP&E Net |
89
|
163
|
160
|
162
|
160
|
161
|
147
|
156
|
157
|
156
|
156
|
149
|
141
|
137
|
676
|
550
|
618
|
|
| PP&E Gross |
89
|
163
|
160
|
162
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
63
|
69
|
76
|
83
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
61
|
29
|
29
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
3
|
3
|
6
|
9
|
9
|
|
| Long-Term Investments |
70
|
70
|
70
|
70
|
70
|
70
|
70
|
70
|
70
|
70
|
68
|
68
|
68
|
68
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
8
|
10
|
2
|
2
|
2
|
2
|
2
|
0
|
2
|
0
|
0
|
92
|
93
|
93
|
|
| Total Assets |
357
N/A
|
301
-16%
|
296
-2%
|
344
+16%
|
364
+6%
|
396
+9%
|
392
-1%
|
418
+7%
|
492
+18%
|
505
+3%
|
517
+3%
|
569
+10%
|
589
+3%
|
680
+15%
|
1 323
+95%
|
2 300
+74%
|
2 560
+11%
|
|
| Liabilities | ||||||||||||||||||
| Accounts Payable |
66
|
15
|
9
|
44
|
59
|
77
|
68
|
70
|
95
|
122
|
82
|
81
|
59
|
77
|
71
|
152
|
132
|
|
| Short-Term Debt |
0
|
0
|
0
|
14
|
21
|
26
|
35
|
22
|
38
|
21
|
45
|
50
|
74
|
101
|
1
|
24
|
64
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
33
|
39
|
|
| Other Current Liabilities |
13
|
13
|
14
|
19
|
16
|
20
|
23
|
31
|
39
|
34
|
46
|
77
|
57
|
63
|
214
|
194
|
212
|
|
| Total Current Liabilities |
79
|
28
|
23
|
77
|
96
|
123
|
125
|
124
|
171
|
177
|
173
|
209
|
190
|
242
|
295
|
403
|
446
|
|
| Long-Term Debt |
16
|
19
|
16
|
5
|
1
|
3
|
2
|
0
|
1
|
3
|
0
|
0
|
0
|
0
|
163
|
132
|
141
|
|
| Deferred Income Tax |
16
|
15
|
13
|
13
|
12
|
13
|
8
|
10
|
9
|
6
|
6
|
4
|
2
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
62
|
61
|
79
|
|
| Other Liabilities |
0
|
0
|
0
|
1
|
3
|
3
|
2
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
28
|
|
| Total Liabilities |
110
N/A
|
61
-44%
|
52
-16%
|
96
+85%
|
112
+16%
|
142
+27%
|
137
-4%
|
135
-1%
|
183
+35%
|
187
+2%
|
179
-4%
|
213
+19%
|
192
-10%
|
242
+26%
|
520
+115%
|
596
+15%
|
693
+16%
|
|
| Equity | ||||||||||||||||||
| Common Stock |
127
|
127
|
127
|
127
|
127
|
127
|
127
|
127
|
127
|
127
|
127
|
127
|
127
|
127
|
180
|
227
|
227
|
|
| Retained Earnings |
51
|
52
|
56
|
59
|
125
|
127
|
129
|
156
|
183
|
191
|
212
|
230
|
271
|
312
|
623
|
1 419
|
1 582
|
|
| Additional Paid In Capital |
69
|
62
|
62
|
62
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
57
|
57
|
|
| Total Equity |
247
N/A
|
240
-3%
|
244
+2%
|
248
+2%
|
252
+2%
|
254
+1%
|
255
+1%
|
282
+11%
|
309
+10%
|
318
+3%
|
338
+6%
|
357
+5%
|
397
+11%
|
438
+10%
|
803
+83%
|
1 704
+112%
|
1 867
+10%
|
|
| Total Liabilities & Equity |
357
N/A
|
301
-16%
|
296
-2%
|
344
+16%
|
364
+6%
|
396
+9%
|
392
-1%
|
418
+7%
|
492
+18%
|
505
+3%
|
517
+3%
|
569
+10%
|
589
+3%
|
680
+15%
|
1 323
+95%
|
2 300
+74%
|
2 560
+11%
|
|
| Shares Outstanding | ||||||||||||||||||
| Common Shares Outstanding |
127
|
127
|
127
|
127
|
127
|
127
|
127
|
127
|
133
|
133
|
133
|
133
|
133
|
133
|
177
|
227
|
227
|
|
Switch to:
Switch to:
See Also
Discover More
